Sorrento Therapeutics (NASDAQ:SRNE) has produced
a preclinical batch of a protein called STI-4398 COVIDTRAP that, it
says, prevents the SARS-CoV-2 virus from infecting respiratory cells.
STI-4398 is a proprietary ACE2
(angiotensin-converting enzyme 2)-Fc fusion protein that binds to a
certain domain of the spike protein of the SARS-CoV-2 virus which blocks
the virus from attaching to cells (spike proteins bind to receptors on
cells in the initial stage of the infection process).
It says STI-4398 COVIDTRAP preserves ACE2 enzyme
activity which is important in maintaining normal blood pressure and
healthy blood flow into the infected lung tissues when used in advanced
COVID-19 patients.
In parallel, company scientists are working to
generate a stable CHO (Chinese Hamster Ovary) manufacturing cell line
that would enable high-yield cGMP production of the COVIDTRAP fusion
protein.
The company expects to complete enabling studies for an expedited IND filing in the next few months.
https://seekingalpha.com/news/3553691-sorrento-up-22-premarket-on-advancement-of-covidminus-19-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.